Similar articles

• [Antiarrhythmic drug therapy in patients with heart failure].

  Nakamura K, Nishii N, Ohe T. Nakamura K, et al. Nihon Rinsho. 2007 May 28;65 Suppl 5:369-74. Nihon Rinsho. 2007. PMID: 17571408 Review. Japanese. No abstract available.
• [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].

  Gronda E, Mangiavacchi M, Andreuzzi B, Municinò A. Gronda E, et al. Ital Heart J Suppl. 2001 Dec;2(12):1278-83. Ital Heart J Suppl. 2001. PMID: 11838348 Review. Italian.
• [Antiarrhythmic therapy in patients with heart failure].

  Faber TS, Zehender M. Faber TS, et al. Ther Umsch. 2000 May;57(5):324-32. doi: 10.1024/0040-5930.57.5.324. Ther Umsch. 2000. PMID: 10859993 Review. German.
• [Prevention of arrhythmia in myocardial infarct (secondary prevention)].

  Gertsch M. Gertsch M. Schweiz Rundsch Med Prax. 1986 Sep 30;75(40):1181-7. Schweiz Rundsch Med Prax. 1986. PMID: 2877483 Review. German. No abstract available.
• Beta-blockers and amiodarone for the primary prevention of sudden cardiac death.

  Frankenberger O, Steinberg JS. Frankenberger O, et al. Curr Cardiol Rep. 1999 Nov;1(4):274-81. doi: 10.1007/s11886-999-0050-8. Curr Cardiol Rep. 1999. PMID: 10980854 Review.